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Abstract
!
Background: The marked increase of type 2 dia-
betes necessitates active development and imple-
mentation of efficient prevention programs. A
European level action has been taken by launch-
ing the IMAGE project to unify and improve the
various prevention management concepts, which
currently exist within the EU. This report de-
scribes the background and the methods used in
the development of the IMAGE project quality in-
dicators for diabetes primary prevention pro-
grams. It is targeted to the persons responsible
for diabetes prevention at different levels of the
health care systems. Methods: Development of
the quality indicators was conducted by a group
of specialists representing different professional
groups from several European countries. Indica-
tors and measurement recommendations were
produced by the expert group in consensus meet-
ings and further developed by combining evi-
dence and expert opinion. Results: The quality in-
dicators were developed for different prevention
strategies: population level prevention strategy,
screening for high risk, and high risk prevention
strategy. Totally, 22 quality indicators were gener-
ated. They constitute the minimum level of qual-
ity assurance recommended for diabetes preven-
tion programs. In addition, 20 scientific evalua-
tion indicators with measurement standards
were produced. These micro level indicators de-
scribe measurements, which should be used if
evaluation, reporting, and scientific analysis are
planned. Conclusions:We hope that these quality
tools together with the IMAGE guidelines will
provide a useful tool for improving the quality of
diabetes prevention in Europe and make different
prevention approaches comparable.
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l.Introduction
!
The increase of type 2 diabetes is a major public
health problem, also within the European Union
(EU). Type 2 diabetes is increasing especially
among working-age populations starting already
in children and adolescents. Even if the preva-
lence of obesity remains stable until 2030, which
seems unlikely, it is anticipated that the number
of people with diabetes will more than double [1,
2]. Clinical studies have shown that even individ-
uals with high risk for diabetes can significantly
reduce their risk and delay the onset of type 2 dia-
betes by adopting a healthy diet, increasing phys-
ical activity, and maintaining or reducing bodytors… Horm Metab Res 2010; 42 (Suppl. 1): S56–S63weight [3–8]. Translating this evidence necessi-
tates active development of efficient prevention
strategies and programs [9]. To fulfil this need,
European level action has been taken by launch-
ing the IMAGE project to unify and improve the
various prevention management concepts, which
currently exist within the EU. IMAGE stands for
“Development and Implementation of a European
Guideline and Training Standards for Diabetes
Prevention” and it builds on the results of the EU
public health research project DE-PLAN “Diabetes
in Europe-Prevention using Lifestyle, Physical Ac-
tivity and Nutritional Intervention”, which relates
to the efficient identification of individuals at
high risk for type 2 diabetes in the community
S57Guidelines
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l.[10]. The objectives of the IMAGE project are: to develop an evi-
dence-based consented European guideline for prevention of
type 2 diabetes and a European curriculum and launch an e-
health training portal for the training of prevention managers
(PM). Furthermore, the project aims to produce European stand-
ards for quality management for these interventions. These ac-
tions will form a unique European-wide evidence-based guid-
ance system to systematically improve the prevention of type 2
diabetes in Europe [10].
Several projects aiming to enhance reporting related to diabetes
have been conducted at the European level. The European Core
Indicators for Diabetes Mellitus (EUCID) project (2006–2007) de-
veloped 27 indicators and demonstrated the feasibility of data
collection in different EU countries and future member states.
The aim of the project was to promote the planning for good dia-
betes health status and diabetes care organization in the different
countries [11]. Many consortia have developed quality indicators
specifically for clinical diabetes care. Despite recommendations,
quality issues or indicators are not often incorporated into the
clinical guidelines [12–16]. The OECD Quality Indicator Project
has published a list of nine health system level quality indicators
of diabetes care [17,18]. In the United States, the Diabetes Quality
Improvement Project (DQIP) has developed and implemented a
widely accepted and comprehensive set of national measures for
evaluation [19]. A working group including participants from 15
EU/EFTA countries has generated an indicator set composed of 31
indicators for monitoring diabetes and its complications within
EU/EFTA countries [20]. In several European countries efforts
have been made to implement quality indicators in diabetes care.
In Saxon, Germany, the Saxon Diabetes Management Programme
has developed an integrated quality management system [21]. A
Belgian study has produced a list of quality indicators for type 2
diabetes by evaluating 125 diabetes guidelines in five European
countries [12]. One group from the Netherlands provided a set
of quality indicators for pharmacological management of type 2
diabetes [22]. In the field of diabetes education, the International
Diabetes Federation has published standards including quality
indicators.
Continuous quality control and evaluation are the key elements
of a successful primary prevention program, and thus, unified
quality standards are necessary for systematical evaluation and
reporting of the prevention programs in the EU and on national
levels [10]. Currently, diabetes prevention programs often lack
methods for systematical follow-up and evaluation and there
are no standardized European level quality indicators for diabetes
prevention. This report describes the background and the meth-
ods used in the development of the quality tools in the IMAGE
project, and present the European quality indicators for diabetes
primary prevention programs. This report also focuses on pri-
mary prevention and is targeted to the persons responsible for
diabetes prevention at different levels of the health care system.Methodology
!
Process of developing indicators
Development of the IMAGE quality management system includ-
ing quality indicators was conducted by a group of specialists
representing different professional groups from several European
countries. Members of the group have been actively involved in
the pivotal studies on diabetes prevention such as the Diabetes
Prevention Study (DPS) [3] and have extensive experience in im-Pajunen P eplementation of the diabetes prevention programs within the
community.
The development of the quality management processes and qual-
ity indicators was based on combining evidence and expert opin-
ion. Indicators were produced by the expert group in consensus
meetings and further developed by a subgroup of experts. The
working group reviewed the existing scientific evidence in the
field. Based on that knowledge, measurement specifications were
designed and the standards of the indicator described. Initially,
109 quality indicators were developed. Further selection re-
vealed 22 quality indicators. In addition, 20 scientific outcome
evaluation indicators were developed. This process included de-
tailed group discussions and additional literature surveys. The fi-
nal approval and selection of the indicators were performedwith
a stepwise approval process in which the participants of the oth-
er IMAGEworking groups gave their comments on the quality in-
dicators before final selection.
Defining target population
The IMAGE quality indicators are presented separately for popu-
lation level and high risk prevention strategies as well as for
screening for high risk. The population level prevention strategy
aims to improve, develop, and implement primary prevention
programs and activities targeting the entire population. From a
societal perspective, this is not the sole responsibility of the
health care sector. Successful population level prevention of dia-
betes involves the participation of different community stake-
holders such as decision makers, educational system, food indus-
try, media, urban planning, and nongovernmental organizations.
Screening for individuals at high risk for type 2 diabetes is essen-
tial for successful interventions. Different methods to screen for
high risk individuals include the use of risk questionnaires, op-
portunistic screening, and computer database searching. Each
country and organization has to develop and introduce a method
suitable for its local needs and resources.
Clinical studies have consistently shown that diabetes can be pre-
vented or at least postponed by lifestyle changes related to
healthy nutrition, adequate amount of physical exercise, and
weight reduction [3–8]. In addition to lifestyle changes, drugs
such as metformin, acarbose, orlistat, and thiazolidinediones can
reduce the relative risk of diabetes in high risk individuals with
impaired glucose tolerance [5,7,25–29]. The aim of the high risk
prevention strategy is to identify high risk individuals and sup-
port them with life-style changes required to reduce their risk
for diabetes and other vascular risk factors.
The quality indicators were generated to be applicable to the
broadest possible population. The definition of high risk popula-
tion used here covers all subjects at risk for type 2 diabetes irre-
spective of the screening method used to identify these individu-
als. They are designed for adults, but not restricted to any specific
age groupwithin the adult population, and are applicable to both
genders, but may not be applicable to different ethnic groups.
Classification of indicators
Structure, process, outcome model
The quality assessment theory by Donabedian is called the struc-
ture/process/outcome (SPO) or the Donabedianʼs Triad Model
[30,31]. This theory comprises three quality elements: structure,
process, and outcome. Structure describes the material and hu-
man resources as well as the organizational structure. This in-
cludes facilities, financing, equipment, and personnel. Process
relates to activities undertaken to achieve objectives such as ac-t al. IMAGE Quality Indicators… Horm Metab Res 2010; 42 (Suppl. 1): S56–S63
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l.tivities related to giving and receiving care or implementing in-
terventions. Outcome describes the effect of care or interventions
on the health status of a subject or population.
The IMAGE quality indicators are classified according to the struc-
ture/process/outcome (SPO) model [30,31] modified so that, for
practical reasons, combined structure/process indicators are pre-
sented. The structure/process indicators constitute the quality
criteria for diabetes prevention and the outcome indicators focus
on outcome evaluation and monitoring. Thus, indicators belong
either to structure/process or outcome categories. The latter in-
clude both intermediate and end-result indicators as appropriate
for the setting. Intermediate outcome indicators reflect changes
in biological status and may be regarded as short-term outcomes
[32].
Macro, meso and micro levels
Indicators are meant for users operating at different levels of the
health care system. At the macro level, indicators are developed
to be utilized by national level decision makers generating the
prerequisite for diabetes/obesity prevention. This means, for ex-
ample, representatives of the national level health institutes or
nongovernmental organizations.
The level of operative primary health care providers is called the
meso level. Depending on the country, indicators may be used by
individuals responsible for activities on diabetes prevention in
municipalities, health districts, health care centers, occupational
care, private sector, or local level nongovernmental organiza-
tions.
At the micro level, the indicators are meant for use by the person-
nel who execute the actual preventive work. This may be a physi-
cian, nurse, dietician, physiotherapist, or prevention manager.
The IMAGE quality indicators are categorized so that the popula-
tion level prevention strategy indicators include macro and meso
level indicators, screening for high risk indicators are applicable
to meso level, and the high risk prevention strategy indicators
for meso and micro levels.
Quality and scientific outcome evaluation indicators
The IMAGE indicators are divided into quality and scientific out-
come evaluation indicators. Quality indicators are the minimum
requirement to be taken into account when conducting preven-
tion activities depending on the level of operator. An additional
set of indicators, scientific outcome evaluation indicators, is pro-
vided for scientific evaluation purposes. Further, measurement
standards for scientific outcome evaluation are provided.Results
!
Quality indicators for diabetes prevention
Population level prevention strategy
At the macro level, a prerequisite for desired outcome in the pop-
ulation level prevention strategy is that policies and legislation
support an environment favoring diabetes prevention. In addi-
tion, each country should have a national diabetes prevention
plan in which specific prevention targets are defined. These tar-
gets should include consideration of the special needs of ethnic
minorities and underprivileged socio-economic groups. Further-
more, policies and legislation should take into account specific
measures needed for the prevention of obesity among children
and adolescent. To enable these tasks, the national health moni-Pajunen P et al. IMAGE Quality Indicators… Horm Metab Res 2010; 42 (Suppl. 1): Storing systems should provide sufficient information for con-
ducting efficient surveillance.
At the health care provider level, processes should support health
promotion including diabetes prevention. The health care pro-
vider should allocate sufficient resources to the preventive work.
Basic knowledge on population level prevention of diabetes/obe-
sity/cardiovascular diseases should be included in the curricula of
the medical professionals working for the health care provider.
Collaboration between different stakeholders active in the health
promotion field should be effective.
In addition to the above mentioned quality criteria on structure
and process, a list of outcome indicators were generated during
the course of the IMAGE work (l" Table 1, upper panel). With
these indicators at hand, decision makers can monitor and evalu-
ate the quality and effectiveness of the selected population level
strategies.
Screening for high risk
Screening is an essential part of the high risk prevention strategy.
In addition, screening protocols can be designed so that they sup-
port also population level prevention activities by increasing the
awareness of the disease. Different screening protocols should be
validated and evaluated at national level. The selected protocols
and strategies should be implemented by the health care pro-
vider. The employed screening protocol should contain a path-
way for diagnostic procedures, as well as defined intervention
strategies for the different subgroups (age, minorities etc.). The
health care provider should promote validated diabetes risk as-
sessment tools. Information technology systems should support
the implementation of screening.
Depending on the health care system, these indicators can be the
responsibility of either macro- or meso levels of operators. In ad-
dition, the indicators in l" Table 1, middle panel, were identified
as outcome indicators for screening for high risk.
High risk prevention strategy
At meso level, every screening strategy should incorporate clini-
cal pathways at the health care provider organization to deal
with individuals at risk for diabetes. The health care provider
should support a multidisciplinary approach for interventions.
High risk prevention strategies should be included in the educa-
tion of the healthcare professionals. The medical record system
should support interventions and chronic disease prevention in
general.
At micro level, the individualʼs risk factor profile should be as-
sessed in the beginning of the intervention process, and the mo-
tivation for behavioral changes explored. Structure and content
of the interventions should be defined and individualized targets
for interventions established. A plan for individual follow-up
should be defined and recorded. The indicators in l" Table 1, low-
er panel, were identified as outcome indicators at meso and mi-
cro levels.
In addition to the quality indicators related to the high risk inter-
vention strategy at micro level, target values which correspond to
the indicators were identified. In the DPS study [3], the following
targets were applied: weight reduction 5% or more, moderate in-
tensity physical activity 30 minutes daily or more, dietary fat less
than 30 E%, saturated fat less than 10 E%, intake of fiber 15 g/1000
kcal (15 g/4200 KJ) or more. These targets may be taken into con-
sideration when planning micro level diabetes prevention. How-
ever, intervention targets should be individualized based on the
baseline evaluation.56–S63
Table 1 Outcome quality indica-
tors for a population level preven-
tion strategy, screening for high
risk, and high risk prevention strat-
egies
Level
Population level prevention strategy
Proportion of population aware of diabetes and its risk factors Macro
Prevalence of diabetes in the population Macro
Percentage of the population physically inactive Macro
Prevalence of overweight, obesity, and abdominal obesity in population Macro
Percentage of population following national recommendations on nutrition Macro
Percentage of health care costs allocated to prevention programs Macro
Proportion of health care personnel per health care provider active in population level primary prevention Meso
Number of health promotion organizations active in population level primary prevention Meso
Screening for high risk
Proportion of the population screened by health care providers per year Meso
The percentage of identified high risk individuals directed to diagnostic procedures Meso
The percentage of identified high risk individuals directed to lifestyle interventions Meso
High risk prevention strategy
Number of healthcare professionals at health care provider level qualified for interventions per
100000 inhabitants
Meso
The percentage of remitted high risk individuals participating in lifestyle interventions Meso
Proportion of individuals dropping out of interventions Meso
Proportion of high risk individuals in interventions achieving clinically significant changes in risk factors at
1 year follow-up
Meso
Diabetes incidence rate among high risk individuals in interventions Meso
Proportion of planned intervention visits completed over 1 year Micro
Weight change over 1 year Micro
Change in waist circumference over 1 year Micro
Change in glucose over 1 year Micro
Change in the quality of nutrition over 1 year Micro
Change in physical activity over 1 year Micro
Table 2 Scientific outcome evalu-
ation indicators and measurement
recommendations
Indicator Unit Reference
Body weight kg FEHES [38], WHO STEPS [39]
BMI kg/m2 FEHES [38], WHO STEPS [39]
Waist circumference cm FEHES [38], WHO STEPS [39]
Fasting and 2-hour OGTT glucose mmol/l WHO [33,34,40]
HbA1c % IFCC [23,24]
Fasting insulin mU/l IFCC [41]
Total energy intake kcal/day IMAGE Toolkit [42,43]
Fat intake E% IMAGE Toolkit [42,43]
Saturated fat intake E% IMAGE Toolkit [42,43]
Fiber intake g/1000 kcal IMAGE Toolkit [42,43]
Physical activity METS [35,44–48]
Fasting total, HDL, and LDL cholesterol cholesterol mmol/l FEHES [38], CDC [49]
Fasting triglycerides mmol/l FEHES [38], CDC [49]
Systolic and diastolic blood pressure mmHg FEHES [38], WHO STEPS [39]
Smoking habits FEHES [38]
Drug treatments EHIS [50]
Costs € IMAGE Evidence-Based Guidelines
Quality of life Score WHO-5 [51], SF-36 [52], SF-12 [53] 15-D [54]
Treatment satisfaction Score DTSQ [55]
S59Guidelines
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l.Scientific outcome evaluation indicators for
diabetes prevention
l" Table 2 presents the recommended scientific evaluation indi-
cators to be used as outcome measures in scientific evaluation of
a diabetes prevention program.
To obtain reliable results, measurements and methods used in
the diabetes prevention programs should be standardized and
valid. l" Table 2 provides the references for the recommended
measurement protocols for the scientific outcome evaluation in-
dicators.Pajunen P eThe standards related to physical measurements (weight, height,
waist circumference, blood pressure) can be found from the Fea-
sibility of European Health Examination Survey (FEHES) recom-
mendations [38] and from the World Health Organization
(WHO), STEPSManual [39]. The FEHES recommendations include
also a questionnaire on smoking habits.
Recommendations on blood sampling and lipid measurements
are available in the FEHES recommendations and in the U.S. Cen-
ter for Disease Control and Prevention (CDC) which has a certifi-
cation program for lipid measurements [49].t al. IMAGE Quality Indicators… Horm Metab Res 2010; 42 (Suppl. 1): S56–S63
S60 Guidelines
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l.The WHO Laboratory Diagnosis and Monitoring of Diabetes Mel-
litus 2002 document provides standards for glucose measure-
ments including the oral glucose tolerance test (OGTT) [40]. Diag-
nosis of diabetes and risk assessment is based on fixed cutoff
points. For this reason all steps in the analytical process require
attention [33]. It is important to notice that preanalytical issues
may seriously affect the quality of the glucose assays. Glucose is
lost through glycolysis and NaF has been used for decades to in-
hibit glycolysis. In addition, ice slurry is often used to prevent
preanalytic loss of glucose. However, new Fluorid-Citrate-mix-
ture tubes allow prolonged storage and transport of the samples
and should be considered to assure a high quality measurement
process [33,34]. Even though this is expected to improve the pre-
cision of glucose measurements, it may increase the number of
individuals diagnosed with diabetes unless compensatory
changes in diagnostic cutoff points are made [33].
The International Federation of Clinical Chemistry and Labora-
tory Medicine (IFCC) has published standards for HbA1c mea-
surements [23,24]. Major differences exist in commercially avail-
able insulin assays. An IFCC working group on the Standardiza-
tion of Insulin Assays has been jointly establishedwith the Amer-
ican Diabetes Association and is currently developing a candidate
reference method for insulin analysis.
There is no consensus on what constitutes adequate measure-
ment and documentation of physical activity or nutrition. Die-
tary pattern and composition can be evaluated with several
methods: food diary, food frequency questionnaire, and check-
list. The selection of a method depends on availability, cultural
background, and resources and cooperativeness of a high risk
person. For accurate calculation of nutrient intakes, culturally
specific food composition databases are mandatory. The quality
of diet in relation to recommendations and dietary changes can
also be assessed based on frequency of consumption of recom-
mendable (e.g., vegetables, fruit, whole grain) and nonrecom-
mendable (e.g., soft drinks, pastries) food items.
Accurate methods to measure physical activity are pedometers
and accelerometers. Self-reported data can be collected via inter-
views, diaries, and recalls. Assessing physical activity should in-
clude: type of activity (e.g., walking, swimming), frequency
(number of sessions), duration, and intensity (level of physical ef-
fort). Using these four components, relative energy expenditure
can be estimated, often referred to metabolic equivalents, METS
[35].
The European Health Interview Survey (EHIS) includes standard-
ized questions on use of medications [50]. Issues related to health
economic evaluation and the costs are presented in the IMAGE
Scientific Guidelines. Quality of life should be measured with
standardized instruments and possible translations should be
certified. Treatment satisfaction can be measured for example
with the Diabetes Treatment Satisfaction Questionnaire: DTSQ
[55].
Micro level data collection form
The data items presented in l" Table 3 are an example of the con-
tent that is recommended to be included and adapted into the lo-
cal version of the data collection tools at the micro level diabetes
prevention. However, the local needs and circumstances are deci-
sive for the final form of the data collection form applied in differ-
ent prevention programs.Pajunen P et al. IMAGE Quality Indicators… Horm Metab Res 2010; 42 (Suppl. 1): SDiscussion
!
As part of the IMAGE project, a set of quality and scientific out-
come evaluation indicators for diabetes prevention programs
were developed together with the development of the IMAGE
evidence-based guideline and the accompanying practical guide
for prevention. Therefore, the indicators are closely linked to the
guideline standards and aremeant to be used in conjunctionwith
the guidelines. The quality indicators are intended to provide
European decision makers, health care providers, and health care
personnel working with prevention activities the tools to moni-
tor, evaluate and improve the quality of diabetes prevention. In
addition, standards of measurements for scientific outcome indi-
cator were identified, aiming to report about the clinical trials
and effectiveness research across Europe, enabling comparisons
between different study groups.
Both individual and population level prevention strategies were
taken into account when developing the indicators. The quality
indicators were selected to represent different dimensions of
preventive work: population level prevention strategy, screening
for high risk, and high risk prevention strategy. To promote the
usability of the indicators, they were generated to be applicable
to the broadest possible population. The definition of high risk
population used covers all subjects at risk for type 2 diabetes ir-
respective of the screening method used in identifying the indi-
viduals.
Some of the macro level outcome indicators require data that can
only be obtained through population-based health surveys. The
Feasibility of a European Health Examination Survey (FEHES) col-
laboration [36], another EU-funded project provides recommen-
dations for organizing standardized health surveys. Further, pop-
ulation level standardized data may be available in the future
through the EUBIROD collaboration [37].
The quality indicators are intended to be used in prospective set-
tings, but may be applicable for retrospective analysis if the qual-
ity of data collection enables this. They comprise the minimum
level of quality standards. Individuals and organizations using
these measures are spurred to involve the scientific evaluation
perspective into the preventive work by using the scientific out-
come evaluation indicators and related instruments described in
themeasurement standards section. High qualitymethodology is
essential to attain reliable and comparable results.
As the responsibility of the implementation of the guidelines dif-
fers depending on the national and local legislation, the imple-
mentation of the guidelines may need adaptation to local regula-
tions and circumstances. At the micro level, individual targets
should be based on individualized baseline evaluation.
Even though data from the pivotal diabetes prevention studies
have proved the effect of preventive interventions, less data are
available on the effectiveness of implementing diabetes preven-
tion into everyday work in primary health care outside of pro-
spective RCTs. Thus, the development of the quality management
processes and quality indicators was based on combining evi-
dence and expert opinion. Some limitations related to the devel-
opment process should be noticed.
Even though the quality indicators are linked to the IMAGE scien-
tific guidelines data standards, target value assignment was diffi-
cult because of lack of data on the general population. It should
be noticed that target values related to weight reduction, nutri-
tion, and physical activity for micro level quality indicators are
drawn from the DPS Study, which was conducted in obese indi-
viduals with impaired glucose tolerance.56–S63
Table 3 Recommended contents
to be included and adapted in the
local versions of the data collection
forms to support, monitor, and
evaluate micro level diabetes pre-
vention
Core items Additional items
Personal data
Personal identification Marital status
Education
Ethnicity
Employment status
Screening
Method used in screening
Risk score type and result (if used)
Reason for intervention
Health and health behavior
Chronic diseases Family history of diabetes and CVD
Regular medications
Smoking:
" never/previously/currently " how often, products used
Physical activity:
" type, frequency, intensity " work-related, commuting, leisure
" method used inmeasuring (e.g., interview, diary,
recall, pedometers, accelerometers)
Nutrition:
" dietary pattern: for example, consumption of
vegetables, fruits, spreads and oil, bread and
cereal (whole/refined grain), sweets, beverages,
alcohol
" energy proportion (E%) of fat, saturated and
trans fat, dietary fiber (g/day, g/1000 kcal), total
energy, alcohol (g, E%), added sugar (g, E%)
" method used inmeasuring (e.g., food diary, food
frequency questionnaire or checklist)
Clinical data (measured)
Body weight 2-hour OGTT glucose
Body height HbA1c
Waist circumference Lipids (total, LDL, HDL cholesterol, and triglycerides)
Fasting glucose Additional measures (fasting insulin, etc)
Systolic and diastolic blood pressure
Content of the intervention
Type of intervention (group, individual, etc.)
Frequency, duration and other details
Targets for the intervention:
" weight, diet, smoking, physical activity
Reinforcement
Success of the intervention
Adherence (proportion of planned intervention
visits completed)
The Diabetes Treatment Satisfaction Questionnaire:
DTSQ
Changes in: health and health behavior
and clinical data
Health related quality of life
Maintenance
Plans how to sustain possible lifestyle changes
after intervention
S61Guidelines
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l.In conclusion, parallel with the development of the IMAGE guide-
lines for the prevention of type 2 diabetes, a quality management
system with quality and scientific outcome evaluation indicators
were developed. The indicators are presented by different levels
of the health care system. They can be used for internal quality
control, as well as for external comparison between operators.
These quality tools complement the IMAGE guidelines and the
prevention manager curriculum, and will provide a useful tool
for improving the quality of diabetes prevention in Europe.Pajunen P eAffiliations
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